Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.

doi:10.1126/science.adk0850

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.

Science (New York, N.Y.) - 7 Jun 2024

Klomp Jennifer E, Diehl J Nathaniel, Klomp Jeffrey A, Edwards A Cole, Yang Runying, Morales Alexis J, Taylor Khalilah E, Drizyte-Miller Kristina, Bryant Kirsten L, Schaefer Antje, Johnson Jared L, Huntsman Emily M, Yaron Tomer M, Pierobon Mariaelena, Baldelli Elisa, Prevatte Alex W, Barker Natalie K, Herring Laura E, Petricoin Emanuel F, Graves Lee M, Cantley Lewis C, Cox Adrienne D, Der Channing J, Stalnecker Clint A

Abstract excerpt

To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein kinases support mutant KRAS-driven cancer growth, we determined the ERK-dependent phosphoproteome in KRAS-mutant pancreatic cancer. We determined that ERK1 and ERK2 share near-identical signaling and transforming outputs and that the KRAS-regulated phosphoproteome is driven nearly completely by ERK. We identified 4666 ERK-dependent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Pancreatic Neoplasms

Share to Phosphoproteins

Share to Proteome

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 38843329
DOI: 10.1126/science.adk0850
PMCID: PMC11301400

Genes

KRAS
RHO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.PMID 38843329Read ↗

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read ↗

ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising.Semantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.Semantic proximity Read ↗

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomasSemantic proximity Read ↗

The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.Semantic proximity Read ↗

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read ↗

Overlapping and Distinct Functions of an Extended Repertoire of KRAS MutationsSemantic proximity Read ↗

Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer.Semantic proximity Read ↗

Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung AdenocarcinomasSemantic proximity Read ↗

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read ↗

KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.